Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elbit Medical Imaging Ltd

This article was originally published in The Gray Sheet

Executive Summary

Israeli firm decides to scuttle a proposed merger with publicly traded subsidiary Elscint Ltd. As outlined in a Feb. 18 proposal, Elbit was to acquire the roughly 43% (7 mil. shares) of Elscint that it did not already own at $14 per share, or $98.2 mil. (1"The Gray Sheet" Feb. 22, p. 12). Elscint received a letter from a committee of Elbit independent directors stating that the proposed business combination "would not be in the best interests of shareholders." Elscint says its board "is in the late stages of a long-term process of evaluating various alternatives to increase shareholder value"
Advertisement

Related Content

Elbit/Elscint
Elbit/Elscint
Advertisement
UsernamePublicRestriction

Register

MT012288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel